Sign In
Buy NRIX
$15.48
-0.89 (-5.44%)
At Close: Jun 03, 2026
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
06:20pm, Friday, 22'nd May 2026
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
07:35am, Monday, 18'th May 2026
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy voluntee
Nurix Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 13'th May 2026
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
04:05pm, Tuesday, 12'th May 2026
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000
04:53pm, Wednesday, 06'th May 2026
Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains.
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
07:00am, Wednesday, 22'nd Apr 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
06:51am, Friday, 17'th Apr 2026
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
10:56am, Friday, 10'th Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable,
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide
03:49pm, Thursday, 09'th Apr 2026
Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 con
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
08:12am, Wednesday, 08'th Apr 2026
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $0.67 per share a year ago.
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
06:00am, Wednesday, 08'th Apr 2026
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Nurix Therapeutics to Participate in Upcoming Investor Conference
07:00am, Tuesday, 07'th Apr 2026
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of “Moderate Buy” from Analysts
02:38am, Monday, 06'th Apr 2026
Shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen analysts that are presently covering the firm, MarketBeat.com repo
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
10:16am, Thursday, 26'th Mar 2026
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
